Bright Minds Biosciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Bright Minds Biosciences | 6-K: Bright Minds Announces Non-Brokered Private Placement Fully Subscribed By Management
Bright Minds Biosciences | 6-K: Condensed Consolidated Interim Financial Statements for the three and nine months ended June 30, 2023 and 2022
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences | 6-K: Bright Minds Announces Effective Date of Share Consolidation
Bright Minds Biosciences | 6-K: Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences | 6-K: MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Bright Minds Biosciences | 6-K: Bright Minds Biosciences to Hold Annual General Meeting on March 24, 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Non-Executive Director Appointment
Bright Minds Biosciences | 6-K: BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS
Bright Minds Biosciences | 6-K: Condensed Consolidated Interim Financial Statements and Management's Discussion and Analysis
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Resignation of Board Member
Bright Minds Biosciences | 6-K: Bright Minds Biosciences announces receipt of NASDAQ notification letter regarding minimum bid price deficiency
Bright Minds Biosciences | 6-K: BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Non-brokered Private Placement
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith as Chief Medical Officer
No Data